| Manufacturers often focus on the costs of hub transition. The bigger risk is inertia. Here's what staying fragmented is costing you.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
The life sciences industry currently has access to more real-world data (RWD) than at any point in its history. | Life sciences…
The most expensive gap in care transitions isn’t the readmission — it’s the handoff | The biggest risk in care transitions isn't…
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…
There’s a thing that happens in American healthcare.You've got these massive systems—pharma conglomerates, hospital networks,…
Life sciences companies are rethinking how they evaluate locations, placing greater emphasis on risk, infrastructure, talent, and…
As biologics have come to supersede small molecules in the biopharma industry’s pipeline, the mounting complexity behind the…
